{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:00:45Z","timestamp":1793325645904,"version":"4.5.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Guideline-recommended antiemetic prophylaxis improves nausea and vomiting control in most patients undergoing chemotherapy. Multinational Association of Supportive Care in Cancer\/European Society for Medical Oncology (MASCC\/ESMO) antiemetic guidelines recommend prophylaxis with a neurokinin-1 receptor antagonist (NK1RA), a 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), and dexamethasone for patients receiving highly emetogenic chemotherapy (HEC), including anthracycline-cyclophosphamide (AC)- and carboplatin (considered moderately emetogenic chemotherapy)-based chemotherapy. Here, we analyze the use of NK1RA\u20135-HT3RA\u2013dexamethasone for antiemetic prophylaxis associated with HEC and carboplatin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The data source was the Global Oncology Monitor (Ipsos Healthcare). Geographically representative physicians from France, Germany, Italy, Spain, and the U.K. were screened for treatment involvement and number of patients treated per month. Patients\u2019 data from January to December 2018 were collected from medical charts and extrapolated on the basis of the total number of physicians who prescribe chemotherapy. The emetic risk of chemotherapy was classified per MASCC\/ESMO guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 45,324 chemotherapy-treated patients were collected, representing a total extrapolated prevalence of 1,394,848 chemotherapy treatments included in the analysis. NK1RAs were used in 45%, 42%, and 19% of patients receiving cisplatin-, AC-, and carboplatin-based chemotherapy, respectively; 18%, 24%, and 7% received the guideline-recommended NK1RA\u20135-HT3RA\u2013dexamethasone combination; no antiemetics were prescribed for 12% of the treatments. Often, physicians\u2019 perception of the emetic risk of chemotherapy did not follow MASCC\/ESMO guideline classification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Low adherence to antiemetic guidelines was revealed in clinical practice in five European countries, with 15% of all HEC-\/carboplatin-based treatments receiving guideline-recommended NK1RA\u20135-HT3RA\u2013dexamethasone prophylaxis and 12% of them receiving no antiemetics. New strategies for improving guideline adherence are urgently needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Despite recent advances in antiemetic therapy, a substantial proportion of patients experience nausea and vomiting associated with chemotherapy in daily clinical practice. Antiemetic guidelines aim at prevention of chemotherapy-induced nausea and vomiting (CINV), and guideline-consistent antiemetic therapy can effectively prevent vomiting and, to a lesser extent, nausea in most patients with cancer. This study reports low adherence to antiemetic guidelines in the highly emetogenic chemotherapy setting in daily clinical practice across five European countries. Opportunity exists to increase adherence to antiemetic guideline recommendations. Implementation of strategies to facilitate guideline adherence can potentially improve CINV control.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13716","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T15:57:50Z","timestamp":1612799870000},"page":"e1073-e1082","source":"Crossref","is-referenced-by-count":57,"title":["Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-8319","authenticated-orcid":false,"given":"Matti","family":"Aapro","sequence":"first","affiliation":[{"name":"Genolier Cancer Centre, Clinique de Genolier, Genolier, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-7208","authenticated-orcid":false,"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[{"name":"Interdisciplinary Cancer Course Department, Gustave Roussy Cancer Center, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-6739","authenticated-orcid":false,"given":"Yolanda","family":"Escobar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-9838","authenticated-orcid":false,"given":"Luigi","family":"Celio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Berman","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8856-0536","authenticated-orcid":false,"given":"Alessandra","family":"Franceschetti","sequence":"additional","affiliation":[{"name":"Ipsos Healthcare, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-2781","authenticated-orcid":false,"given":"Danielle","family":"Bell","sequence":"additional","affiliation":[{"name":"Ipsos Healthcare, Mahwah, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-5938","authenticated-orcid":false,"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"2022020821443452900_onco13716-bib-0001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","article-title":"Preference weights for chemotherapy side effects from the perspective of women with breast cancer","volume":"142","author":"Kuchuk","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2022020821443452900_onco13716-bib-0002","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","article-title":"Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer","volume":"13","author":"Sun","year":"2005","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0003","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","article-title":"Chemotherapy-induced nausea and vomiting in clinical practice: Impact on patients\u2019 quality of life","volume":"20","author":"Fern\u00e1ndez-Ortega","year":"2012","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0004","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00520-014-2325-x","article-title":"Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): Multinational survey results from 2388 health care providers","volume":"23","author":"Van Laar","year":"2015","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022020821443452900_onco13716-bib-0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"2022020821443452900_onco13716-bib-0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","article-title":"International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice","volume":"722","author":"Jordan","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2022020821443452900_onco13716-bib-0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","article-title":"Proposal for classifying the acute emetogenicity of cancer chemotherapy","volume":"5","author":"Hesketh","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022020821443452900_onco13716-bib-0009","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013state of the art","volume":"19","author":"Grunberg","year":"2011","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0010","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"2022020821443452900_onco13716-bib-0011","year":"2019"},{"key":"2022020821443452900_onco13716-bib-0012","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"2022020821443452900_onco13716-bib-0013","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022020821443452900_onco13716-bib-0014","volume-title":"Akynzeo (netupitant and palonosetron) capsules; Akynzeo (fosnetupitant and palonosetron) for injection [prescribing information]","year":"2020"},{"key":"2022020821443452900_onco13716-bib-0015","volume-title":"Cinvanti (aprepitant) injectable emulsion [prescribing information]","year":"2019"},{"key":"2022020821443452900_onco13716-bib-0016","volume-title":"Varubi (rolapitant) tablets; Varubi (rolapitant) injectable emulsion [prescribing information]","year":"2018"},{"key":"2022020821443452900_onco13716-bib-0017","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/annonc\/mdy187","article-title":"New formulation, new drug? The importance of assessing the safety of new supportive care formulations in oncology","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"},{"key":"2022020821443452900_onco13716-bib-0018"},{"key":"2022020821443452900_onco13716-bib-0019","volume-title":"Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with use of VARUBI (rolapitant) injectable emulsion","author":"Tesaro, Inc","year":"2018"},{"key":"2022020821443452900_onco13716-bib-0020","volume-title":"Varubi IV distribution suspension","author":"ASD Healthcare","year":"2018"},{"key":"2022020821443452900_onco13716-bib-0021","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1185\/03007995.2011.556603","article-title":"Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC\/MEC\/HEC)","volume":"27","author":"Schwartzberg","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2022020821443452900_onco13716-bib-0022","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: Results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2022020821443452900_onco13716-bib-0023","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"2022020821443452900_onco13716-bib-0024","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00520-017-3585-z","article-title":"Prevention of chemotherapy-induced nausea: The role of neurokinin-1 (NK1) receptor antagonists","volume":"25","author":"Bo\u0161njak","year":"2017","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0025","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"2022020821443452900_onco13716-bib-0026","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"key":"2022020821443452900_onco13716-bib-0027","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0028","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00520-010-1079-3","article-title":"Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting","volume":"20","author":"Burmeister","year":"2012","journal-title":"Support Care Cancer"},{"issue":"suppl 15","key":"2022020821443452900_onco13716-bib-0029","doi-asserted-by":"crossref","first-page":"11595a","DOI":"10.1200\/JCO.2019.37.15_suppl.11595","article-title":"Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC \u22654","volume":"37","author":"Navari","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022020821443452900_onco13716-bib-0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mdj078","article-title":"Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference","volume":"17","author":"Roila","year":"2006","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"2022020821443452900_onco13716-bib-0031","first-page":"3439a","article-title":"Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLS) adherence based on real-world prescribing data","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann Oncol"},{"key":"2022020821443452900_onco13716-bib-0032","article-title":"Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey","volume":"1","author":"Aapro","year":"2018","journal-title":"Cancer Rep"},{"key":"2022020821443452900_onco13716-bib-0033","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: Results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0034","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1007\/s00520-019-04697-1","article-title":"Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): Results of a European oncology nurse survey","volume":"27","author":"Dielenseger","year":"2019","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0035","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"2022020821443452900_onco13716-bib-0036","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdx120","article-title":"Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): A novel approach","volume":"28","author":"Scott\u00e9","year":"2017","journal-title":"Ann Oncol"},{"key":"2022020821443452900_onco13716-bib-0037","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00520-015-2809-3","article-title":"Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study","volume":"23","author":"Escobar","year":"2015","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0038","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","article-title":"Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists","volume":"19","author":"Majem","year":"2011","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0039","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","article-title":"Communicating about chemotherapy-induced nausea and vomiting: A comparison of patient and provider perspectives","volume":"10","author":"Salsman","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"2022020821443452900_onco13716-bib-0040","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00520-015-2750-5","article-title":"Impact and management of chemotherapy\/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists\/oncology nurses and patients: A cross-sectional multinational survey","volume":"23","author":"Vidall","year":"2015","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0041","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022020821443452900_onco13716-bib-0042","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00520-018-4323-x","article-title":"What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study","volume":"27","author":"Childs","year":"2019","journal-title":"Support Care Cancer"},{"key":"2022020821443452900_onco13716-bib-0043","first-page":"211","article-title":"Evidence-based management of chemotherapy-induced nausea and vomiting: A position statement from a European cancer nursing forum","volume":"5","author":"Vidall","year":"2011","journal-title":"Ecancermedicalscience"},{"key":"2022020821443452900_onco13716-bib-0044","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2003.08.118","article-title":"Improving the care of patients with regard to chemotherapy-induced nausea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines","volume":"21","author":"Mertens","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022020821443452900_onco13716-bib-0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1200\/JCO.1998.16.2.771","article-title":"Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center","volume":"16","author":"Nolte","year":"1998","journal-title":"J Clin Oncol"},{"key":"2022020821443452900_onco13716-bib-0046","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/fon-2020-0187","article-title":"Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: Effects on quality of life","volume":"16","author":"Karthaus","year":"2020","journal-title":"Future Oncol"},{"key":"2022020821443452900_onco13716-bib-0047","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/cer-2018-0104","article-title":"Real-world effectiveness of palonosetron-based antiemetic regimens: Preventing chemotherapy-induced nausea and vomiting","volume":"8","author":"Schwartzberg","year":"2019","journal-title":"J Comp Eff Res"},{"key":"2022020821443452900_onco13716-bib-0048","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J Support Oncol"},{"key":"2022020821443452900_onco13716-bib-0049","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022020821443452900_onco13716-bib-0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.colegn.2016.10.009","article-title":"Remote real-time monitoring for chemotherapy side-effects in patients with blood cancers","volume":"24","author":"Breen","year":"2017","journal-title":"Collegian"},{"key":"2022020821443452900_onco13716-bib-0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CMENT.S40219","article-title":"A novel digital patient-reported outcome platform for head and neck oncology patients\u2013a pilot study","volume":"9","author":"Peltola","year":"2016","journal-title":"Clin Med Insights Ear Nose Throat"},{"key":"2022020821443452900_onco13716-bib-0052","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e1073\/42375918\/oncolo_26_6_e1073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e1073\/42375918\/oncolo_26_6_e1073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T21:53:24Z","timestamp":1644357204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/6\/e1073\/6520983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,17]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13716","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,3,17]]}}}